Clinical Study

Qbgj398-301- A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study Of Oral Infigratinib Versus Gemcitabine With Cisplatin In Subjects With Advanced/Metastatic Or Inoperable Cholangiocarcinoma With Fgfr2 Gene Fusions/Translocations: The Proof Tri

Posted Date: May 22, 2020

  • Investigator: Olugbenga Olowokure
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The primary goal of this study is to determine if treatment with infigratinib improves PFS as assessed by BICR compared to treatment with gemcitabine and cisplatin in subjects with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions/ translocations


To Be Eligible: Must Have Unresectable Locally Advanced Or Metastatic Cholangiocarcinoma, Ecog =1, Life Expectancy >3 Months, No Prior Malignancy Within 3 Years, No Active Or History Of Infection Or Disease Impacting Safety In The Study,


Cholangiocarcinoma, Bile Duct Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.